The importance of genomic testing in CLL and its role in clinical decision-making

Chronic lymphocytic leukemia (CLL) remains a challenging hematological malignancy to treat, and genomic testing has become increasingly important in this disease. Several genomic tests are commonly carried out prior to initiating treatment, including testing for TP53 aberrations, IgHV mutational status, and more. 

In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, and Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, who discuss the importance of genomic testing in CLL and how this impacts treatment decisions.